89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

Core Insights - The company is making significant progress with its FGF21 analog, pegozafermin, with three ongoing Phase III studies [2] - The SHTG program has completed enrollment, with results expected early next year [2] - Two MASH programs are also in progress, targeting pre-cirrhotic MASH and compensated cirrhosis populations, which are seen as having high unmet medical needs [2] Study Updates - The SHTG program is the first to complete enrollment, with pivotal study results anticipated in early 2024 [2] - The MASH programs include one focused on pre-cirrhotic MASH, which is currently enrolling patients, and another targeting compensated cirrhosis, also in the enrollment phase [2] - The potential impact of FGF21 in MASH, particularly for patients with cirrhosis, is viewed as transformative [2]